Shinobi Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $59M

  • Investors
  • 10

Shinobi Therapeutics General Information

Description

Developer of cell therapies designed for comprehensive immune evasion. The company is developing a new class of hyperimmune CD8ab iPS-T cells for cancer and other genetic diseases, enabling healthcare industry to use immune therapies to treat diseases.

Contact Information

Formerly Known As
Evade Biotechnology, Thyas
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 270 Littlefield Avenue
  • South San Francisco, CA 94080
  • United States
+1 (888)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 270 Littlefield Avenue
  • South San Francisco, CA 94080
  • United States
+1 (888)

Shinobi Therapeutics Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shinobi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 06-Aug-2024 $59M Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 01-Aug-2024 Completed Pre-Clinical Trials
2. Seed Round $27.3M $27.3M Completed Startup
1. Merger of Equals 12-Dec-2023 Completed Startup
To view Shinobi Therapeutics’s complete valuation and funding history, request access »

Shinobi Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
Series II
Series I-3
Series I-2 2,360,059 $0.000010 $0.88 $0.88 1x $0.88 2.43%
Series I-1 2,124,000 $0.000010 $0.81 $0.81 1x $0.81 2.19%
To view Shinobi Therapeutics’s complete cap table history, request access »

Shinobi Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell therapies designed for comprehensive immune evasion. The company is developing a new class of hyperimm
Drug Discovery
South San Francisco, CA
40 As of 2026

Seattle, WA
 

Brookhaven, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shinobi Therapeutics Competitors (52)

One of Shinobi Therapeutics’s 52 competitors is Mozart Therapeutics, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mozart Therapeutics Venture Capital-Backed Seattle, WA
iCell Gene Therapeutics Accelerator/Incubator Backed Brookhaven, NY
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Synthekine Venture Capital-Backed Menlo Park, CA
You’re viewing 5 of 52 competitors. Get the full list »

Shinobi Therapeutics Patents

Shinobi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025220666-A1 Cytotoxic lymphocytes expressing variable region-deleted t cell receptors Pending 16-Apr-2024
EP-4798627-A2 Sirp alpha engager cells Pending 27-Oct-2023
AU-2024369017-A1 Sirpα engager cells Pending 27-Oct-2023
WO-2025090961-A2 Sirpα engager cells Inactive 27-Oct-2023
WO-2025090961-A3 Sirpα engager cells Inactive 27-Oct-2023 A61K35/17
To view Shinobi Therapeutics’s complete patent history, request access »

Shinobi Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shinobi Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Astellas Venture Management Corporate Venture Capital Minority
D3 (Tokyo) Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Fast Track Initiative Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Shinobi Therapeutics Acquisitions (1)

Shinobi Therapeutics’s most recent deal was a Merger/Acquisition with Thyas. The deal was made on 12-Dec-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Thyas 12-Dec-2023 Merger/Acquisition Biotechnology
To view Shinobi Therapeutics’s complete acquisitions history, request access »

Shinobi Therapeutics FAQs

  • When was Shinobi Therapeutics founded?

    Shinobi Therapeutics was founded in 2023.

  • Where is Shinobi Therapeutics headquartered?

    Shinobi Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Shinobi Therapeutics?

    Shinobi Therapeutics has 40 total employees.

  • What industry is Shinobi Therapeutics in?

    Shinobi Therapeutics’s primary industry is Drug Discovery.

  • Is Shinobi Therapeutics a private or public company?

    Shinobi Therapeutics is a Private company.

  • What is Shinobi Therapeutics’s current revenue?

    The current revenue for Shinobi Therapeutics is .

  • How much funding has Shinobi Therapeutics raised over time?

    Shinobi Therapeutics has raised $78.3M.

  • Who are Shinobi Therapeutics’s investors?

    Astellas Venture Management, D3 (Tokyo), Eight Roads, EQT Life Sciences, and Fast Track Initiative are 5 of 10 investors who have invested in Shinobi Therapeutics.

  • Who are Shinobi Therapeutics’s competitors?

    Mozart Therapeutics, iCell Gene Therapeutics, Neurona Therapeutics, Sangamo Therapeutics, and Synthekine are some of the 52 competitors of Shinobi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process